Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL877932 | 0.92 | KMT2A (0.47) | KMT2AMEN1KDM4EHSD17B10TSHR | |
| SCHEMBL877579 | 0.87 | KMT2A (0.50) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL875118 | 0.87 | TSHR (0.52) | KMT2AMEN1KDM4ETSHRGPR139 | |
| SCHEMBL874492 | 0.86 | KMT2A (0.49) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL874387 | 0.84 | KMT2A (0.48) | KMT2AMEN1KDM4EHSD17B10TSHR | |
| SCHEMBL875318 | 0.84 | KMT2A (0.46) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL874410 | 0.84 | HTT (0.54) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL875017 | 0.84 | HTT (0.47) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL874274 | 0.83 | MMP2 (0.48) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL526249 | 0.83 | KMT2A (0.48) | KMT2AMEN1KDM4EHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | claimed |
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| EP-2619185-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038942-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP12, MMP10 | KMT2A 3501/4885MEN1 1755/4885KDM4E 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.